How much revenue does J. B. Chemicals & Pharmaceuticals make?

J. B. Chemicals & Pharmaceuticals reported 38.62 billion INR in revenue for fiscal year 2025, up 12.0% from 34.48 billion INR in fiscal year 2024. In Q3 2026 revenue was 10.65 billion INR.

Where does J. B. Chemicals & Pharmaceuticals make most of its revenue?

India: 58% of revenue by region in fiscal year 2025, followed by outside India (42%).

What companies are similar to J. B. Chemicals & Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ipca Laboratories Limited (IPCALAB.NS), GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS), Ajanta Pharma Limited (AJANTPHARM.NS), Emcure Pharmaceuticals L (EMCURE.NS).

J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS) Stock

About J. B. Chemicals & Pharmaceuticals Limited

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosa...

At a glance

J. B. Chemicals & Pharmaceuticals reported revenue of 38.62 billion INR for fiscal year 2025, up 12.0% from fiscal year 2024, and net income of 6.60 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 10.65 billion INR, up 10.5% from a year before. India was its largest region in fiscal year 2025, with 58% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.